>Marché du diagnostic du cancer de la prostate au Moyen-Orient et en Afrique, par type de produit (instruments, réactifs et consommables et accessoires), type de diagnostic (tests de dépistage préliminaires, tests de confirmation), groupe d'âge (adulte, pédiatrie et gériatrie), type (adénocarcinome prostatique, carcinome à petites cellules et autres), stade (cancer de la prostate localisé, cancer de la prostate récurrent/avancé et cancer de la prostate résistant à la castration (métastatique et non métastatique)), type d'échantillon (sang, tissu, urine et autres), utilisateur final (laboratoires de diagnostic indépendants, hôpitaux, instituts de recherche sur le cancer, cliniques, centres de chirurgie ambulatoire et autres), canal de distribution (appel d'offres direct, ventes au détail), pays (Afrique du Sud, Arabie saoudite, Émirats arabes unis, Égypte, Israël et reste du Moyen-Orient et de l'Afrique) Tendances de l'industrie et prévisions jusqu'en 2028
Analyse et perspectives du marché : marché du diagnostic du cancer de la prostate au Moyen-Orient et en Afrique
Le marché du diagnostic du cancer de la prostate devrait connaître une croissance de marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 12,9% au cours de la période de prévision de 2021 à 2028 et devrait atteindre 320,40 millions USD d'ici 2028. L'accent croissant mis sur la charge de morbidité et la sensibilisation croissante à la maladie sont les principaux moteurs qui propulsent le marché du diagnostic du cancer de la prostate au cours de la période de prévision.
Le cancer de la prostate débute lorsque les cellules de la prostate commencent à se développer à un rythme anormal. On parle alors de cancer de la prostate. La prostate est une glande que l'on trouve uniquement chez les hommes. Elle produit une partie du liquide qui entre dans la composition du sperme. Le diagnostic du cancer de la prostate est une technique de détection du cancer principalement à un stade précoce pour mener à bien l'approche thérapeutique future qui peut augmenter le taux de survie.
Le développement du cancer de la prostate est étroitement lié à l'âge, avec l'augmentation de la population gériatrique, on observe une augmentation significative de l'incidence du cancer de la prostate. Cela augmentera la demande de produits de diagnostic pour la détection de la maladie et devrait agir comme un moteur pour le marché du diagnostic du cancer de la prostate. Le test PSA est l'un des principaux tests utilisés pour la détection du cancer de la prostate. Cependant, les contradictions entre le gouvernement et les prestataires de services médicaux concernant l'utilisation du PSA et des tests associés devraient restreindre le marché du diagnostic du cancer de la prostate. Le marché a un énorme potentiel de croissance et avec l'entrée de nouveaux acteurs du marché essayant d'entrer sur le marché en utilisant l'expansion commerciale via des accords de distribution et ayant investi dans le diagnostic du cancer de la prostate, on s'attend à ce que la taille du marché augmente et constituera une opportunité pour le marché du diagnostic du cancer de la prostate. L'obstacle lié à la réalisation du test de diagnostic du cancer peut affecter la vie de la population et c'est l'un des aspects les plus difficiles à surmonter en ce qui concerne les pays à faible revenu, ce qui affecte donc la communauté du diagnostic et constitue un défi pour le marché du diagnostic du cancer de la prostate.
Le rapport sur le marché du diagnostic du cancer de la prostate fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, les changements dans la réglementation du marché, les approbations de produits, les décisions stratégiques, les lancements de produits, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché du diagnostic du cancer de la prostate, contactez Data Bridge Market Research pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché du diagnostic du cancer de la prostate
Le marché du diagnostic du cancer de la prostate est classé en huit segments notables qui sont basés sur le type de produit, le type de diagnostic, la tranche d'âge, le type, le stade, le type d'échantillon, les utilisateurs finaux et le canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- Sur la base du type de produit, le marché du diagnostic du cancer de la prostate est segmenté en instruments, réactifs et consommables et accessoires. En 2021, le segment des réactifs et consommables domine le marché du diagnostic du cancer de la prostate car il comprend les produits de test PSA, qui constituent le principal test recommandé pour les tests préliminaires.
- On the basis of diagnostics type, the prostate cancer diagnostics market is segmented into preliminary screening tests and confirmatory tests. In 2021, preliminary screening tests segment is dominating in the prostate cancer diagnostics market as the number of preliminary tests surpass the number of confirmatory tests by significant percentage.
- On the basis of age group, the prostate cancer diagnostics market is segmented into adult, pediatric and geriatrics. In 2021, geriatrics segment is dominating in the prostate cancer diagnostics market as around 60% of cases are diagnosed in men over 65 year of age.
- On the basis of type, the prostate cancer diagnostics market is segmented into prostatic adenocarcinoma, small cell carcinoma and others. In 2021, prostatic adenocarcinoma segment dominates the prostate cancer diagnostics market because more than 95 percent of prostate cancers are adenocarcinomas which develop in the gland cells and line of the prostate gland.
- On the basis of stage, the prostate cancer diagnostics market is segmented into localized prostate cancer, recurrent/advanced prostate cancer and castration-resistant prostate cancer (metastatic and non-metastatic). In 2021, localized prostate cancer segment dominates the prostate cancer diagnostics market as approximately 80 percent to 85 percent of all prostate cancers are detected in the local or regional stages which represent stages I, II and III.
- On the basis of sample type, the prostate cancer diagnostics market is segmented into blood, tissue, urine and others. In 2021, blood segment is dominating the prostate cancer diagnostics market as blood is the primary sample for the most common preliminary test that is PSA test and due to easy availability of blood, less complex procedure of blood sample collection doesn’t take much time which is expected to dominate the prostate cancer diagnostics market.
- On the basis of end users, the prostate cancer diagnostics market is segmented into independent diagnostic laboratories, hospitals, cancer research institutes, clinics, ambulatory surgical centers and others. In 2021, independent diagnostic laboratories segment is dominating the prostate cancer diagnostics market as the segment is specialized in conducting various prostate cancer diagnostics.
- On the basis of distribution channel, the prostate cancer diagnostics market is segmented into direct tender and retail sales. In 2021, direct tender segment dominates the prostate cancer diagnostics market as they are the primary source of procurement of reagents, consumables, devices and accessories by healthcare organizations and diagnostic labs.
Prostate Cancer Diagnostics Market Country Level Analysis
The prostate cancer diagnostics market is analysed and market size information is provided by the country, product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel as referenced above.
The countries covered in the prostate cancer diagnostics market report are the South Africa, Saudi Arabia, UAE, Egypt, Israel & Rest of Middle East and Africa.
South Africa is expected to grow in the forecast period of 2021 to 2028 due to increasing focus on prostate cancer diagnostics products and rising awareness about it.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic Initiatives by manufactures is Creating New Opportunities for Players in the Prostate Cancer Diagnostics Market
The prostate cancer diagnostics market also provides you with detailed market analysis for every country growth in prostate cancer diagnostics product sales, impact of advancement in the prostate cancer diagnostics and changes in regulatory scenarios with their support for the prostate cancer diagnostics market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Prostate Cancer Diagnostics Market Share Analysis
The prostate cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to prostate cancer diagnostics market.
The major companies providing prostate cancer diagnostics market are F. Hoffmann-La Roche Ltd, ACON Laboratories, Inc., HUMASIS, Teco Diagnostics, Hologic Inc., Accuquik Test Kits, MDxHealthcare, Abbott, Siemens Healthcare GmbH, OPKO Health Inc., Myraid Genetics, Inc., DiaSorin S.p.A, Beckman Coulter, Inc. (a subsidiary of Danaher), Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation), bioMérieux SA, Metamark Genetics, Inc., Prostatype Genomics, Fujirebio, Proteomedix, Eurolyser Diagnostica GmbH among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the prostate cancer diagnostics market.
For instance,
- En janvier 2021, Hologic Inc. a annoncé avoir conclu un accord pour acquérir SOMATEX, Inc., pour 64 millions USD. Cette société est le fournisseur de biomarqueurs pour le cancer. Après l'acquisition complète, Hologic Inc. prendra un élan dans le domaine des biomarqueurs oncologiques mondiaux et élargira le portefeuille de produits de l'entreprise pour les patients atteints de cancer, ce qui contribuera aux ventes et aux revenus futurs de l'entreprise.
- En août 2020, HUMASIS a annoncé avoir passé avec succès l'examen préliminaire d'introduction en bourse à la Bourse de Corée le mois dernier après avoir subi un processus d'évaluation technique par une agence d'évaluation professionnelle en novembre de l'année dernière et qu'elle obtiendrait bientôt l'approbation pour la cotation à la bourse coréenne. Ce sera une réussite pour l'entreprise et stimulera l'expansion commerciale et les stratégies commerciales futures de l'entreprise.
La collaboration, les coentreprises et d’autres stratégies des acteurs du marché améliorent le marché des entreprises sur le marché du diagnostic du cancer de la prostate, ce qui offre également l’avantage aux organisations d’améliorer leur offre pour le marché du diagnostic du cancer de la prostate.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USERS COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EPIDEMIOLOGY
5 COMPARATIVE ANALYSIS WITH PARENT MARKET
6 REGULATORY FRAMEWORK: MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET
6.1 REGULATORY SCENARIO IN THE U.S.
6.2 REGULATORY SCENARIO IN EUROPEAN UNION
6.3 REGULATORY SCENARIO IN JAPAN
6.4 REGULATORY SCENARIO IN CHINA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF PROSTATE CANCER
7.1.2 INCREASE RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTIC
7.1.3 INCREASE IN GERIATRIC POPULATION
7.1.4 LAUNCH OF NEW PRODUCTS FOR PROSTATE CANCER DIAGNOSTIC
7.1.5 DISEASE CAUSING PROSTATE CANCER
7.2 RESTRAINTS
7.2.1 CONTROVERSY RELATED TO PSA TESTING
7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE
7.2.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7.3 OPPORTUNITIES
7.3.1 RISING INVESTMENT AND FUNDING BY EMERGING PLAYERS
7.3.2 REIMBURSEMENT POLICY FOR PROSTATE CANCER DIAGNOSIS
7.3.3 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS
7.3.4 RISING SURVIVAL RATE DUE TO EARLY DIAGNOSIS OF PROSTATE CANCER
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY REQUIREMENT FOR DIAGNOSTIC PRODUCTS
7.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTICS TESTS
7.4.3 INACCURATE DIAGNOSIS RESULTS
8 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION BY MANUFACTURERS MADE DURING COVID-19 PANDEMIC
8.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
8.6 CONCLUSION
9 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 REAGENTS & CONSUMABLES
9.3 INSTRUMENTS
9.4 ACCESSORIES
10 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE
10.1 OVERVIEW
10.2 PRELIMINARY SCREENING TESTS
10.2.1 PROSTATE-SPECIFIC ANTIGEN (PSA) TEST
10.2.2 DIGITAL RECTAL EXAM (DRE) TEST
10.3 CONFIRMATORY TESTS
10.3.1 PCA3 TEST
10.3.2 BIOPSY
10.3.3 IMAGING TESTS
10.3.3.1 ULTRASOUND
10.3.3.2 MAGNETIC RESONANCE IMAGING (MRI)
10.3.3.2.1 MULTIPARAMETRIC MRI
10.3.3.2.2 MRI FUSION-GUIDED PROSTATE BIOPSY
10.3.3.3 CT SCAN
10.3.3.4 BONE SCAN
10.3.3.5 PET/CT SCAN
10.3.4 BIOMARKER
10.3.4.1 RNA BIOMARKERS
10.3.4.2 DNA BIOMARKERS
10.3.4.3 PROTEIN BIOMARKERS
11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE
11.1 OVERVIEW
11.2 PROSTATIC ADENOCARCINOMA
11.3 SMALL CELL CARCINOMA
11.4 OTHERS
12 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP
12.1 OVERVIEW
12.2 GERIATRICS
12.3 ADULT
12.4 PEDIATRIC
13 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE
13.1 OVERVIEW
13.2 LOCALIZED PROSTATE CANCER
13.3 RECURRENT/ADVANCED PROSTATE CANCER
13.4 CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC)
14 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE
14.1 OVERVIEW
14.2 BLOOD
14.3 TISSUE
14.4 URINE
14.5 OTHERS
15 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS
15.1 OVERVIEW
15.2 INDEPENDENT DIAGNOSTIC LABORATORIES
15.3 HOSPITALS
15.4 CLINICS
15.5 AMBULATORY SURGICAL CENTERS
15.6 CANCER RESEARCH INSTITUTES
15.7 OTHERS
16 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
17 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY
17.1 MIDDLE EAST & AFRICA
17.1.1 SOUTH AFRICA
17.1.2 SAUDI ARABIA
17.1.3 UAE
17.1.4 ISRAEL
17.1.5 EGYPT
17.1.6 REST OF MIDDLE EAST & AFRICA
18 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
19 SWOT
20 COMPANY PROFILE
20.1 F. HOFFMANN-LA ROCHE LTD
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLI0
20.1.5 RECENT DEVELOPMENTS
20.2 ABBOTT
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 SIEMENS HEALTHCARE GMBH
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 OPKO HEALTH INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 ACCUQUIK TEST KITS
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.7 ACON LABORATORIES INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENTS
20.8 BIOMERIEUX SA
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 DIASORIN S.P.A
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLI0
20.9.4 RECENT DEVELOPMENTS
20.1 EUROLYSER DIAGNOSTICA GMBH
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENT
20.11 FUJIREBIO
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLI
20.11.3 RECENT DEVELOPMENTS
20.12 GENOMIC HEALTH, INC., (A SUBSIDIARY OF EXACT SCIENCES CORPORATION)
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENTS
20.13 HOLOGIC, INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENTS
20.14 HUMASIS
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENTS
20.15 MDXHEALTHCARE
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENTS
20.16 METAMARK GENETICS, INC.
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLI0
20.16.3 RECENT DEVELOPMENTS
20.17 MYRAID GENETICS, INC.
20.17.1 COMPANY SNAPSHOT
20.17.2 REVENUE ANALYSIS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT DEVELOPMENTS
20.18 PROSTATYPE GENOMICS
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 PROTEOMEDIX
20.19.1 COMPANY SNAPSHOT
20.19.2 PRODUCT PORTFOLIO
20.19.3 RECENT DEVELOPMENTS
20.2 TECO DIAGNOSTICS
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Liste des tableaux
LIST OF TABLES
TABLE 1 CATEGORIZATION UNDER THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA '88) OF 1988
TABLE 2 AGE AND PROBABILITY OF DEVELOPING PROSTATE CANCER
TABLE 3 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 2019-2028 (UNITS)
TABLE 5 MIDDLE EAST AND AFRICA REAGENTS & CONSUMABLES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA INSTRUMENTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA ACCESSORIES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA CONFIRMATORY TESTSIN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA PROSTATIC ADENOCARCINOMAS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION
TABLE 13 MIDDLE EAST AND AFRICA SMALL CELL CARCINOMA IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA GERIATRICS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA SEVERE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA SEVERE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA LOCALIZED PROSTATE CANCER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA RECURRENT/ADVANCED PROSTATE CANCER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA BLOOD IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA TISSUE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA URINE IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA HOSPITALS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA CLINICS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA CANCER RESEARCH INSTITUTES IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA DIRECT TENDER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA HOSPITALS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)
TABLE 41 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 53 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 54 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)
TABLE 55 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 56 SOUTH AFRICA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 57 SOUTH AFRICA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 58 SOUTH AFRICA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 59 SOUTH AFRICA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 60 SOUTH AFRICA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 61 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)
TABLE 62 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 64 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 67 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 68 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)
TABLE 69 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 70 SAUDI ARABIA PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 71 SAUDI ARABIA CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 72 SAUDI ARABIA IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 73 SAUDI ARABIA MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 74 SAUDI ARABIA BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 75 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)
TABLE 76 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 81 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 82 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)
TABLE 83 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 84 UAE PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 85 UAE CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 86 UAE IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 87 UAE MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 88 UAE BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 89 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)
TABLE 90 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 92 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 93 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 94 UAE PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 96 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)
TABLE 97 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 98 ISRAEL PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 99 ISRAEL CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 100 ISRAEL IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 101 ISRAEL MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 102 ISRAEL BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 103 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)
TABLE 104 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 106 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 107 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 108 ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 109 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 110 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (UNITS)
TABLE 111 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 112 EGYPT PRELIMINARY SCREENING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 113 EGYPT CONFIRMATORY TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 114 EGYPT IMAGING TESTS IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 115 EGYPT MAGNETIC RESONANCE IMAGING (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 116 EGYPT BIOMARKER IN PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2019-2028 (USD MILLION)
TABLE 117 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2019-2028 (USD MILLION)
TABLE 118 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 119 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 120 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2019-2028 (USD MILLION)
TABLE 121 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 122 EGYPT PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 123 REST OF MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
Liste des figures
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: MARKET END USERS COVERAGE GRID
FIGURE 10 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 12 INCREASING PREVALENCE OF PROSTATE CANCER AND INCREASED RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTICS ARE DRIVING THE MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET IN 2021 & 2028
FIGURE 14 REGULATORY FRAMEWORK FOR APPROVAL PROCESS IN CHINA
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET
FIGURE 16 ESTIMATED INCIDENCE CASES OF PROSTATE CANCER, ALL AGES
FIGURE 17 GERIATRIC POPULATION IN THE EUROPEAN REGION
FIGURE 18 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2020
FIGURE 19 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2020-2028 (USD MILLION)
FIGURE 20 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2021-2028)
FIGURE 21 PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, 2020
FIGURE 23 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE 2020-2028 (USD MILLION)
FIGURE 24 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, CAGR (2021-2028)
FIGURE 25 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTICS TYPE, LIFELINE CURVE
FIGURE 26 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020
FIGURE 27 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 28 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 29 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2020
FIGURE 31 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP , 2020-2028 (USD MILLION)
FIGURE 32 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2021-2028)
FIGURE 33 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, 2020
FIGURE 35 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, 2020-2028 (USD MILLION)
FIGURE 36 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2021-2028)
FIGURE 37 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2020
FIGURE 39 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2020-2028 (USD MILLION)
FIGURE 40 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2021-2028)
FIGURE 41 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 42 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, 2020
FIGURE 43 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, 2020-2028 (USD MILLION)
FIGURE 44 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 45 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY END USERS, LIFELINE CURVE
FIGURE 46 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 47 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 48 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 49 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION, LIFELINE CURVE
FIGURE 50 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2020)
FIGURE 51 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020)
FIGURE 52 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 53 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 54 MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2021-2028)
FIGURE 55 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
